Procter & Gamble Health Limited (BOM:500126)
6,218.65
-18.15 (-0.29%)
At close: Jun 16, 2026
Procter & Gamble Health Revenue
In the fiscal year ending March 31, 2026, Procter & Gamble Health had annual revenue of 14.08B INR with 15.59% growth. Procter & Gamble Health had revenue of 3.70B in the quarter ending March 31, 2026, with 19.12% growth.
Revenue
14.08B
Revenue Growth
+15.59%
P/S Ratio
7.33
Revenue / Employee
10.62M
Employees
1,326
Market Cap
103.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 14.08B | 1.90B | 15.59% |
| Mar 31, 2025 | 12.18B | 667.90M | 5.80% |
| Jun 30, 2024 | 11.51B | -783.60M | -6.37% |
| Jun 30, 2023 | 12.30B | 1.15B | 10.34% |
| Jun 30, 2022 | 11.14B | 1.06B | 10.48% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 82.80B |
| Granules India | 53.66B |
| Viyash Scientific | 34.20B |
| AstraZeneca Pharma India | 22.76B |
| Caplin Point Laboratories | 21.87B |
| FDC Limited | 21.71B |
| Sanofi India | 17.74B |
| Rubicon Research | 17.54B |
Procter & Gamble Health News
- 9 months ago - P&G Health appoints Shashank Srowthy as Executive Director and CFO, effective October 1 - Business Upturn
- 11 months ago - P&G Health shares surge 8% as Q1 revenue jumps 19.5% YoY to Rs 339 crore - Business Upturn
- 1 year ago - P&G Health Q2 FY25: Revenue rises 2.8% YoY to Rs 313.41 crore, net profit surges 25.6% to Rs 82.33 crore - Business Upturn
- 1 year ago - Procter & Gamble Health Q2 FY25 results: Stock jumps 2% ahead of result announcement - Business Upturn